TY - JOUR
T1 - Uric acid and contrast-induced nephropathy
T2 - An updated review and meta-regression analysis
AU - Pelliccia, Francesco
AU - Pasceri, Vincenzo
AU - Patti, Giuseppe
AU - Marazzi, Giuseppe
AU - De Luca, Giuseppe
AU - Tanzilli, Gaetano
AU - Viceconte, Nicola
AU - Speciale, Giulio
AU - Mangieri, Enrico
AU - Gaudio, Carlo
N1 - Publisher Copyright:
© 2018 Termedia Sp. z o.o. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Introduction: Previous studies have suggested a relationship between serum uric acid and contrast-induced nephropathy (CIN). Aim: We performed an updated review and a meta-regression analysis to assess whether serum uric acid is associated with CIN or there exists any relationship between serum uric acid and other risk factors for CIN. Material and methods: We searched PubMed, Embase and Cochrane databases and reviewed cited references up to July 31, 2018 to identify relevant studies. Results: A total of 6,705 patients from 10 clinical studies were included. CIN occurred in 774 of the 6,705 (12%) patients. Baseline uric acid levels were significantly higher in those who developed CIN (6.51 vs. 5.67 mg/dl; 95% CI: 0.55-1.22, p = 0.00001). Comparison of clinical features showed that patients with CIN were significantly older (69 vs. 63 years; p < 0.00001) and more often had diabetes (42% vs. 32%; p = 0.002) and hypertension (67% vs. 59%; p = 0.03). Also, patients who developed CIN had lower hemoglobin (12.5 vs. 13.6 mg/dl; p < 0.00001) and higher levels of baseline creatinine (1.27 vs. 1.01 mg/dl; p < 0.0001), but had similar levels of glycemia, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride. Also, they showed a lower ejection fraction (45% vs. 50%; p < 0.00001). Meta-regression analysis revealed that uric acid related only to age (r = 0.13, p = 0.03). Conclusions: Our investigation indicates that uric acid is significantly associated with CIN. Uric acid correlated significantly with age only, and not with other major predictors of CIN. Further studies are therefore needed to verify the potential of uric acid to improve CIN risk stratification.
AB - Introduction: Previous studies have suggested a relationship between serum uric acid and contrast-induced nephropathy (CIN). Aim: We performed an updated review and a meta-regression analysis to assess whether serum uric acid is associated with CIN or there exists any relationship between serum uric acid and other risk factors for CIN. Material and methods: We searched PubMed, Embase and Cochrane databases and reviewed cited references up to July 31, 2018 to identify relevant studies. Results: A total of 6,705 patients from 10 clinical studies were included. CIN occurred in 774 of the 6,705 (12%) patients. Baseline uric acid levels were significantly higher in those who developed CIN (6.51 vs. 5.67 mg/dl; 95% CI: 0.55-1.22, p = 0.00001). Comparison of clinical features showed that patients with CIN were significantly older (69 vs. 63 years; p < 0.00001) and more often had diabetes (42% vs. 32%; p = 0.002) and hypertension (67% vs. 59%; p = 0.03). Also, patients who developed CIN had lower hemoglobin (12.5 vs. 13.6 mg/dl; p < 0.00001) and higher levels of baseline creatinine (1.27 vs. 1.01 mg/dl; p < 0.0001), but had similar levels of glycemia, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride. Also, they showed a lower ejection fraction (45% vs. 50%; p < 0.00001). Meta-regression analysis revealed that uric acid related only to age (r = 0.13, p = 0.03). Conclusions: Our investigation indicates that uric acid is significantly associated with CIN. Uric acid correlated significantly with age only, and not with other major predictors of CIN. Further studies are therefore needed to verify the potential of uric acid to improve CIN risk stratification.
KW - Angiography
KW - Contrast-induced nephropathy
KW - Percutaneous coronary intervention
KW - Uric acid
UR - http://www.scopus.com/inward/record.url?scp=85058713805&partnerID=8YFLogxK
U2 - 10.5114/aic.2018.79870
DO - 10.5114/aic.2018.79870
M3 - Article
SN - 1734-9338
VL - 14
SP - 399
EP - 412
JO - Postepy w Kardiologii Interwencyjnej
JF - Postepy w Kardiologii Interwencyjnej
IS - 4
ER -